{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Water-only+fasting&page=2",
    "query": {
      "intervention": "Water-only fasting",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Water-only+fasting&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T21:30:42.643Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01190150",
      "title": "Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Menorrhagia"
      ],
      "interventions": [
        {
          "name": "tranexamic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "16 Years",
        "sex": "FEMALE",
        "summary": "12 Years to 16 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2010-08",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2012-07-16",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01190150"
    },
    {
      "nct_id": "NCT04327141",
      "title": "Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Weight Loss",
        "Gut Microbiome",
        "Anti-Aging"
      ],
      "interventions": [
        {
          "name": "P-IF",
          "type": "BEHAVIORAL"
        },
        {
          "name": "HH",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Skidmore College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-09-03",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-04-08",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Saratoga Springs, New York",
      "locations": [
        {
          "city": "Saratoga Springs",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04327141"
    },
    {
      "nct_id": "NCT00768183",
      "title": "Comparison of KADIAN 100 mg When Dosed With Alcohol Under Fasting and Fed Conditions Compared to Water",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "KADIAN Capsule + alcohol (under fasting conditions)",
          "type": "DRUG"
        },
        {
          "name": "KADIAN Capsule + water (under fasting conditions)",
          "type": "DRUG"
        },
        {
          "name": "morphine sulfate IR oral solution + water",
          "type": "DRUG"
        },
        {
          "name": "KADIAN Capsule + alcohol (under fed conditions)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "40 Years",
        "sex": "MALE",
        "summary": "21 Years to 40 Years · Male only"
      },
      "enrollment_count": 32,
      "start_date": "2006-05",
      "completion_date": "2006-07",
      "has_results": false,
      "last_update_posted_date": "2020-07-16",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Lincoln, Nebraska",
      "locations": [
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00768183"
    },
    {
      "nct_id": "NCT02925546",
      "title": "A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Heart Failure, Congestive"
      ],
      "interventions": [
        {
          "name": "GSK2798745 Micronized API without SLS and hypermellose (Tablet A)",
          "type": "DRUG"
        },
        {
          "name": "GSK2798745 Micronized API with SLS and hypermellose (Tablet B)",
          "type": "DRUG"
        },
        {
          "name": "GSK2798745 milled API without SLS and hypermellose (Tablet C)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2016-10",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-01-25",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02925546"
    },
    {
      "nct_id": "NCT03964038",
      "title": "A Study to Assess the Relative Bioavailability of Gilteritinib Following a Single Dose of Gilteritinib Mini-tablet Oral Suspension and Gilteritinib Mini-tablets Compared to a Single Dose of Gilteritinib Tablet in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "gilteritinib",
          "type": "DRUG"
        },
        {
          "name": "gilteritinib mini tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 48,
      "start_date": "2019-05-21",
      "completion_date": "2019-07-16",
      "has_results": false,
      "last_update_posted_date": "2024-10-16",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03964038"
    },
    {
      "nct_id": "NCT01879748",
      "title": "A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Rasagiline",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "20 Years to 50 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-06",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2013-12-20",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01879748"
    },
    {
      "nct_id": "NCT04274075",
      "title": "Evaluation of the Relative Bioavailability and Food Effect of GDC-9545 in Healthy Females of Non-Childbearing Potential",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "GDC-9545 Tablet, Fasted: Treatment A",
          "type": "DRUG"
        },
        {
          "name": "GDC-9545 Capsule, Fasted: Treatment B",
          "type": "DRUG"
        },
        {
          "name": "GDC-9545 Capsule, Fed: Treatment C",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 65 Years · Female only"
      },
      "enrollment_count": 18,
      "start_date": "2020-03-06",
      "completion_date": "2020-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-04-28",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Daytona Beach, Florida",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04274075"
    },
    {
      "nct_id": "NCT05002231",
      "title": "Relative Bioavailability and Food Effect Study of Losmapimod 15 mg Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Adult Subjects"
      ],
      "interventions": [
        {
          "name": "Losmapimod 15 mg oral tablet",
          "type": "DRUG"
        },
        {
          "name": "Losmapimod two 7.5 mg oral tablets",
          "type": "DRUG"
        },
        {
          "name": "Losmapimod one 15 mg oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fulcrum Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2021-08-19",
      "completion_date": "2021-10-22",
      "has_results": false,
      "last_update_posted_date": "2021-11-12",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05002231"
    },
    {
      "nct_id": "NCT01759394",
      "title": "A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Avatrombopag maleate 40 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 36,
      "start_date": "2012-10",
      "completion_date": "2013-03",
      "has_results": false,
      "last_update_posted_date": "2013-10-31",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01759394"
    },
    {
      "nct_id": "NCT02411435",
      "title": "Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "CAB",
          "type": "DRUG"
        },
        {
          "name": "RIF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2015-07",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2016-01-06",
      "last_synced_at": "2026-09-25T21:30:42.643Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02411435"
    }
  ]
}